COPN: Recurring revenue up 18% YoY, but operating loss widened; Winlevi and pipeline advanced
Revenue grew 18% YoY to €49.6m, led by strong Derma and Gastro/CDMO segments, but operating loss widened to €6.6m due to higher expenses and lower project-based revenue. Winlevi expanded in Europe, and the pipeline advanced with key regulatory milestones.Original document: Cosmo Pharmaceuticals NV…